Neuroendocrine differentiation (NED) in prostate cancer is a well-recognized phenotypic
change by which prostate cancer cells transdifferentiate into neuroendocrine-like (NE-like) …

Androgen deprivation therapy (ADT) has been the standard care for patients with advanced
prostate cancer (PC) since the 1940s. Although ADT shows clear benefits for many patients …

Objectives To assess chromogranin A (CGA) and neuron‐specific enolase (NSE) levels and
changes in these at different stages of prostatic adenocarcinoma (PCA). Methods Overall …

Purpose The natural history of prostate cancer (PC) almost always evolves to castration-
resistant prostate cancer (CRPC) status, sometimes comprising pure or mixed …

Once castration-resistant prostate cancer (CRPC) become resistant for cabazitaxel
treatment, the patients are obliged to best supportive care. Therefore, the elucidation of the …

Abstract Lessons Learned Patients with metastatic castration-resistant prostate cancer did
not tolerate the combination of alisertib with abiraterone and prednisone. There was no clear …

Purpose: To evaluate whether serum neuroendocrine markers could effectively predict
treatment outcomes in patients with metastatic castration-resistant prostate cancer …

Objectives To explore the association of chromogranin A (CgA) levels and the risk of poorly
differentiated prostate cancer (CaP) in men undergoing prostate biopsy. Materials and …

Methods: Complete records of 223 of the 489 patients with metastatic PC were obtained
from computerized data based system in a tertiary care hospital in north India between …

Cushing's syndrome (CS) due to ectopic adrenocorticotropic hormone (ACTH) secretion
(EAS) can result from a variety of tumours and rarely from those of prostatic origin. We …